Introduction
============

Among the nosocomial pathogens, *Pseudomonas aeruginosa*, a gram-negative non-fermenting bacillus, is particularly worrisome because of its intrinsic resistance against multiple antimicrobial agents which reduces treatment options.[@b1-idr-11-1225],[@b2-idr-11-1225] Carbapenems are widely used as first-line drugs to treat nosocomial infections and are effective against multidrug-resistant *P. aeruginosa* and other bacterial infections producing the cephalosporinase AmpC or extended-spectrum β-lactamases.[@b3-idr-11-1225] Nevertheless, carbapenem-resistant *P. aeruginosa* (CRPA) isolates are increasingly observed, probably due to the global clinical use of carbapenem.[@b4-idr-11-1225]--[@b6-idr-11-1225] In 2017, surveys reported by the World Health Organization on multi-country antibiotic resistance revealed that CRPA is regarded as the second ranked critical-priority bacteria among 20 bacterial species with 25 patterns of acquired resistance.[@b7-idr-11-1225] CRPA strains often exhibit cross-resistance to other antibiotics such as cephalosporins, quinolones, and aminoglycosides, which are partially responsible for the multidrug resistance characteristics.[@b8-idr-11-1225] Therefore, physicians have to make more difficult decisions for empirically treating the patients infected with CRPA. Of note, we observed some clinical *P. aeruginosa* isolates that exhibited a phenotype of antibiotic resistance: resistance to carbapenems, but susceptibility to broad-spectrum cephalosporins (Carb-R/Ceph-S). In these cases, cephalosporins could be used as an alternative drug to treat these patients, especially in some countries (including China) where polymyxins are not commercially available. In addition, polymyxins have a narrow therapeutic window, and major adverse effects related to their parenteral use are neurotoxicity and nephrotoxicity. To date, only two previous studies have focused on the resistance mechanisms of Carb-R/Ceph-S *P. aeruginosa* infections.[@b9-idr-11-1225],[@b10-idr-11-1225] However, the clinical significance of this phenomenon is currently unknown. Data regarding the identification of patients with Carb-R/Ceph-S *P. aeruginosa* bacteremia may assist clinicians in deciding upon treatments. To the best of our knowledge, this retrospective analysis is the first comprehensive study to evaluate the mechanisms, risk factors, and clinical outcomes for nosocomial patients with Carb-R/Ceph-S *P. aeruginosa* bacteremia. It should be noted that we used the case--case--control study design to explore the factors associated with Carb-R/Ceph-S *P. aeruginosa* bacteremia, which could be an effective and more accurate method to reduce the biases caused by comparing traditional resistant and susceptible isolates. Moreover, predictors for mortality in patients with Carb-R/Ceph-S *P. aeruginosa* infections were also identified in our study.

Patients and methods
====================

Study setting and study design
------------------------------

This retrospective case--case--control study was conducted in a 3,200-bed tertiary university-affiliated hospital located in Southwest China. We searched the clinical microbiology database of our hospital to identify the cases with the following characteristics: *P. aeruginosa* bacteremia diagnosed between January 2011 and December 2017; only the first *P. aeruginosa* bacteremia episode was considered in our study; if bacteremia occurred \>14 days after the first positive blood culture, it was considered as a new episode; patients with polymicrobial bacteremia were excluded; and patients in all groups admitted for \<48 hours and duplicate isolates were also excluded.

The three study groups were defined as follows: the first case group consisted of patients with Carb-R/Ceph-S *P. aeruginosa* bacteremia during hospitalization (case I group); the second case group consisted of patients with a positive blood culture for Carb-S/Ceph-S *P. aeruginosa* during hospitalization (case II group); and the control group consisted of randomly selected patients hospitalized during the same period of time (at a 2:1 ratio to the case group) with non-*P. aeruginosa* bloodstream infections.

In our study, we conducted a three-part analysis: 1) a retrospective case--case--control study in which the Carb-R/Ceph-S and the Carb-S/Ceph-S groups were compared with the control group (no *P. aeruginosa* bacteremia) to evaluate the risk factors for the isolation of Carb-R/Ceph-S and Carb-S/Ceph-S *P. aeruginosa*; 2) a retrospective cohort study in which the Carb-R/Ceph-S group and the Carb-S/Ceph-S group were compared to provide the potential predictors specifically associated with the acquisition of Carb-R/Ceph-S *P. aeruginosa* bacteremia; and 3) a retrospective study to determine the 30-day mortality associated with the isolation of Carb-R/Ceph-S *P. aeruginosa* bacteremia.

Isolates identification and antimicrobial susceptibility testing
----------------------------------------------------------------

Blood cultures were processed in the clinical microbiology laboratory at our hospital using an automated blood culture system (BACTEC 860 system; Becton Dickinson Diagnostic Instrument Systems, Sparks, MD, USA). *P. aeruginosa* was identified using the VITEK 2 Compact system or the VITEK MS system (bioMérieux, Marcy l'Etoile, France). Antimicrobial susceptibilities were determined in vitro using a VITEK 2 Compact AST-GN09 card (bioMérieux). All the carbapenem-resistant (resistant to at least one carbapenem drug, including imipenem and meropenem) and cephalosporin-susceptible (susceptible to both ceftazidime and cefepime) isolates were confirmed manually by the standard broth microdilution method. *P. aeruginosa* ATCC 27853 was used as a quality control strain during the antimicrobial susceptibility testing, and the results were interpreted using criteria based on the Clinical and Laboratory Standards Institute guidelines.[@b11-idr-11-1225]

Molecular characterization and resistance mechanisms
----------------------------------------------------

Polymerase chain reaction analyses for the presence of carbapenemase-encoding genes (bla~KPC~, bla~VIM~, bla~IMP~, bla~NDM~, and bla~OXA-48-like~) and β-lactamase-encoding genes (bla~CTX-M~, bla~TEM~, and bla~SHV~) was performed by using primers and conditions described previously.[@b12-idr-11-1225],[@b13-idr-11-1225] In addition, the resistance mechanisms were analyzed with four representative Carb-R/Ceph-S *P. aeruginosa* isolates by real-time reverse transcription polymerase chain reaction, as described in a previous study.[@b10-idr-11-1225]

Data collection
---------------

Patient demographics and clinical data were obtained from their electronic medical records and clinical microbiology laboratory databases. Cases and controls were compared using the following parameters as potential risk factors: 1) demographics (age and sex); 2) hospitalization characteristics (surgical ward, transfer from another hospital, 30-day readmission, and intensive care unit \[ICU\] admission); 3) primary source of infection (urinary tract infection, respiratory tract infection, intra-abdominal infection, and unknown source), underlying diseases, and primary admission diagnosis (diabetes, hypertension, lung disease, heart disease, hepatobiliary disease, gastrointestinal disease, renal disease, and malignancy); 4) previous surgery or other invasive devices before a positive culture (mechanical ventilation, total parenteral nutrition, urinary catheter, drainage tube, nasogastric tube, tracheal intubation, central venous catheter, and blood product transfusion); 5) the recent receipt of antibiotics (patients received antibiotics within 3 months before a first positive culture was obtained) and antifungal agents (including fluconazole, voriconazole, itraconazole, amphotericin B, and flucytosine); and 6) patient outcomes (length of stay before a positive culture, total length of hospital stay, 30-day mortality, and functional status deterioration).

Definitions
-----------

Carb-R/Ceph-S *P. aeruginosa* bacteremia was defined by the blood culture positivity for a *P. aeruginosa* strain that was resistant to at least one carbapenem (imipenem and/or meropenem), but susceptible to broad-spectrum cephalosporins (both ceftazidime and cefepime). Septic shock was defined as sepsis associated with organ dysfunction, accompanied by persistent hypotension following volume replacement.[@b14-idr-11-1225] Severe anemia was defined as a hemoglobin level \<60 g/L. Hypoproteinemia was defined as serum total protein or albumin levels of \<60 and \<25 g/L, respectively. Hypokalemia was defined as a serum potassium level \<3.5 mmol/L. Neutropenia was defined as an absolute neutrophil count of \<500 cells/µL. Corticosteroid use was defined as administration of \>20 mg/day of prednisone or methylprednisolone for at least 4 weeks. The source of the bacteremia was determined on the basis of the isolation of *P. aeruginosa* from the presumed portal of entry and clinical evaluation. The primary site of bacteremia was classified into two categories: high-risk source (respiratory tract infection, intra-abdominal infection, and unknown origin) and low-risk source (urinary tract infection).[@b15-idr-11-1225] Adequate treatment was considered when an antimicrobial regimen that included an active antimicrobial was administered within 24 hours after the blood culture samples were obtained; otherwise, if the antimicrobials used empirically were not sensitive, it was considered as inadequate treatment. In addition, the patients who had not received antimicrobial therapy (either empirical or definitive) were also classified into inadequate treatment.

Statistical analysis
--------------------

All analyses were performed using SPSS statistical software (version 22.0; IBM Corporation, Armonk, NY, USA). Categorical variables were presented as frequencies and percentages and were compared using a McNemar test. Continuous variables were presented as medians and inter-quartile ranges and were compared using Student's *t*-test (normally distributed variables) and Wilcoxon rank sum test (non-normally distributed variables). Odds ratios (ORs) and 95% CIs were calculated to evaluate the strength of any association. To eliminate confounding variables in predicting the risk factors for developing Carb-R/Ceph-S *P. aeruginosa* bacteremia, all variables with *P*\<0.1 by univariate analysis were enrolled into a multivariate logistic regression model for further assessment. Survival curves were constructed using the Kaplan--Meier method, and the log-rank test was used for comparisons between deceased and survived groups. All *P*-values were two-tailed, and *P*\<0.05 was considered significant.

Ethical considerations
----------------------

The data and the samples analyzed in the present study were obtained in accordance with the standards and approval of the Chongqing Medical University Institutional Review Board and Biomedical Ethics Committee. The ethics committee waived the need for written informed consent provided by participants due to the retrospective nature of the study. Because all patient data were analyzed in anonymity, no additional informed consent was required.

Results
=======

Patient characteristics
-----------------------

During the study period, 203 episodes of *P. aeruginosa* nosocomial bloodstream infections occurred in 180 patients. Sixty-three patients were identified to have Carb-R/Ceph-S *P. aeruginosa* bacteremia (case I group), who were matched to 63 patients with Carb-S/Ceph-S *P. aeruginosa* bacteremia (case II group). In addition, 126 control patients with bloodstream infections other than *P. aeruginosa* were randomly matched to each of the case I and case II groups at a 2:1 ratio. Thus, 252 patients were available for evaluation in the final study cohort ([Figure 1](#f1-idr-11-1225){ref-type="fig"}). The epidemiological and baseline characteristics of the patients are listed in [Table 1](#t1-idr-11-1225){ref-type="table"}. Of the patients exhibiting Carb-R/Ceph-S *P. aeruginosa* bacteremia, most patients (69.8%) were male, the median age was 63 years, and infections were more frequent in surgical wards (57.1%). All the episodes resulted from nosocomial acquisition, and the median duration of the total hospital stay was 30 days. Notably, hepatobiliary disease and hematologic malignancy were the most frequent underlying diseases in Carb-R/Ceph-S and Carb-S/Ceph-S *P. aeruginosa* bacteremia, respectively.

Antimicrobial susceptibility testing
------------------------------------

Of the 63 Carb-R/Ceph-S *P. aeruginosa* strains evaluated, all isolates displayed resistance to imipenem and 45 (71.4%) strains showed resistance to meropenem. In addition, all isolates were susceptible to both ceftazidime and cefepime. For fluoroquinolones, 15 (23.8%) isolates were resistant to ciprofloxacin and 15 (23.8%) were resistant to levofloxacin. For aminoglycosides, 14 (22.2%) isolates were resistant to gentamicin and 10 (15.9%) were resistant to tobramycin. Moreover, 17.5% (11/63) of Carb-R/Ceph-S *P. aeruginosa* isolates were identified as being multidrug resistant, as they were resistant to three or more classes of antimicrobials.

Resistance mechanism of Carb-R/Ceph-S *P. aeruginosa*
-----------------------------------------------------

For resistance mechanisms regarding the Carb-R/Ceph-S *P. aeruginosa*, none of the isolates collected in our study possessed carbapenemases or extended-spectrum β-lactamase-encoding genes. Of these non-MBL-producing isolates, four isolates were selected to search for the presence of other resistance mechanisms, such as AmpC, the efflux pump, and OprD porin. As shown in [Figure 2](#f2-idr-11-1225){ref-type="fig"}, our results revealed that overexpression of efflux systems (primarily related to the *mexB* and *mexD* efflux genes) and decreased expression of OprD could have contributed to the Carb-R/Ceph-S phenotype of *P. aeruginosa* isolates.

Analysis of case I group vs controls
------------------------------------

The risk factors for the acquisition of Carb-R/Ceph-S *P. aeruginosa* (case I group) are shown in [Table 1](#t1-idr-11-1225){ref-type="table"}. In the univariate analysis, patients with Carb-R/Ceph-S *P. aeruginosa* bacteremia had higher frequencies in 30-day readmission than the uninfected controls. For underlying diseases and conditions, the case I group showed a higher incidence of having hematologic malignancy and hepatobiliary disease compared with controls. Moreover, the primary site of bacteremia was more likely to have been intra-abdominally derived for case patients. Compared to the uninfected controls, patients with Carb-R/Ceph-S *P. aeruginosa* bacteremia were frequently subjected to invasive procedures such as mechanical ventilation, total parenteral nutrition, and central venous catheterization. Additionally, hypoproteinemia and hypokalemia were significantly more common among case patients than among uninfected controls. Regarding previous antibiotic exposure, carbapenems and antifungal agents were significantly associated with the acquisition of Carb-R/Ceph-S *P. aeruginosa* bacteremia. In the multivariate analysis, 30-day readmission (OR, 11.03; 95% CI, 3.27--37.15; *P*\<0.001), total parenteral nutrition (OR, 18.98; 95% CI, 3.94--91.54; *P*\<0.001), central venous catheterization (OR, 5.85; 95% CI, 2.09--16.33; *P*=0.001), and exposure to carbapenems (OR, 11.41; 95% CI, 3.38--38.56; *P*\<0.001) were independently associated with Carb-R/Ceph-S *P. aeruginosa* bacteremia when compared with the control group ([Table 2](#t2-idr-11-1225){ref-type="table"}).

Analysis of case II group vs controls
-------------------------------------

In univariate analyses listed in [Table 1](#t1-idr-11-1225){ref-type="table"}, risk factors for Carb-S/Ceph-S *P. aeruginosa* bacteremia (case II group) were observed to be significant in underlying diseases, such as hematologic malignancy and hepatobiliary disease. Devices and invasive procedures indicated increased risk of bacteremia, but only the receipt of total parenteral nutrition, central venous catheterization, and nasogastric tube were statistically significant. Moreover, case patients were more likely to receive chemoradiotherapy than uninfected controls. In contrast with the case I group, no significant difference was observed in the primary site of bacteremia and antibiotics exposure between case II group and controls. Multivariate analysis showed that hematologic malignancy (OR, 3.98; 95% CI, 1.56--10.17; *P*=0.004) and total parenteral nutrition (OR, 19.89; 95% CI, 5.94--66.58; *P*\<0.001) were independently associated with Carb-S/Ceph-S *P. aeruginosa* bacteremia when compared with the control group ([Table 2](#t2-idr-11-1225){ref-type="table"}).

Analysis of case I group vs case II group
-----------------------------------------

When the third model examining the case I and case II groups was analyzed to specifically evaluate the acquisition of Carb-R/Ceph-S *P. aeruginosa* bacteremia, the results showed that intra-abdominal--related bacteremia, mechanical ventilation, central venous catheterization, nasogastric tube, and exposure to aminoglycosides and carbapenems were significant in the univariate analysis. We observed that exposure to carbapenems (OR, 2.65; 95% CI, 1.17--6.01; *P*=0.020) was the only independent risk factor associated with the isolation of Carb-R/Ceph-S *P. aeruginosa* in the multivariate analysis ([Tables 1](#t1-idr-11-1225){ref-type="table"} and [2](#t2-idr-11-1225){ref-type="table"}).

Outcome study: in-hospital mortality
------------------------------------

The results of the univariate and multivariate analyses of predictors for mortality are shown in [Table 3](#t3-idr-11-1225){ref-type="table"}. Elderly (≥60 years) patients, admission to ICU, multiple organ dysfunction syndrome, and septic shock were significant in univariate analysis. In the multivariate model, admission to an ICU (OR, 3.16; 95% CI, 1.11--8.95; *P*=0.031) and septic shock (OR, 4.22; 95% CI, 1.45--12.32; *P*=0.008) were independent risk factors associated with mortality. Additionally, the Kaplan--Meier survival analysis ([Figure 3](#f3-idr-11-1225){ref-type="fig"}) showed that the cumulative probability of death in the 30 days after bacteremia was significantly different (*P*=0.035), as the 30-day mortality cumulative probability of death was 27.0% (17/63) for Carb-R/Ceph-S *P. aeruginosa* bacteremia and 12.7% (8/63) for Carb-S/Ceph-S *P. aeruginosa* bacteremia.

Discussion
==========

Considering that CRPA bacteremia is a life-threatening illness with higher costs and increased mortality, the phenotype of Carb-R/Ceph-S *P. aeruginosa* deserves particular attention, especially in some countries where polymyxins are not available for clinical practice. To the best of our knowledge, this is the first analysis to investigate the risk factors and clinical outcomes in patients with Carb-R/Ceph-S *P. aeruginosa* bacteremia by using a case--case--control study design. A key finding in this study is that 30-day readmission is an independent risk factor for Carb-R/Ceph-S *P. aeruginosa* isolation. Moreover, another important finding is that a high prevalence of hematologic malignancy could be significantly associated with Carb-S/Ceph-S *P. aeruginosa* bacteremia.

In the present study, central venous catheterization was observed to be independently associated with Carb-R/Ceph-S *P. aeruginosa* bacteremia, and this association has been well established by other studies with respect to CRPA bacteremia.[@b16-idr-11-1225] This finding highlights the importance of infection control practices to prevent the extraluminal microbial colonization of the insertion site via some invasive procedures into the bloodstream. Interestingly, our data identified 30-day readmission as a novel independent predictor associated with Carb-R/Ceph-S *P. aeruginosa* bacteremia, a factor for which no other study has reported significance. One possibility is that compared with other patients with an initial admission, patients with 30-day readmission, compared with other patients with an initial admission, could have more severe and multiple comorbidities that put them at a higher risk for the development of Carb-R/Ceph-S *P. aeruginosa* bacteremia. On the other hand, it is also possible that these patients are more vulnerable to acquiring nosocomial pathogens in the same environment due to their 30-day readmission. This observation should advocate for physicians to provide more attentive care to patients who are readmitted in the short term.

Interestingly, parenteral nutrition was the only predictor identified in both the Carb-R/Ceph-S and Carb-S/Ceph-S *P. aeruginosa* groups compared with the controls. However, no significant difference was observed in the two case groups, revealing that parenteral nutrition could be associated with *P. aeruginosa* bacteremia in general. Multiple factors could contribute to this association. First, patients receiving parenteral nutrition may have impaired intestinal mucosal structure, disrupted gut barrier functions, and increased microbe translocation, thus providing opportunities for the occurrence of bacteremia.[@b17-idr-11-1225] Second, most parenteral nutrition formulas contain some glucose, an important carbohydrate that is essential to the body. Hyperglycemia may increase bacterial adherence and biofilm formation, thus increasing bacterial infections rates, especially for certain microorganisms associated with invasive procedures, such as *P. aeruginosa*.[@b18-idr-11-1225] Third, intestinal mucosal atrophy, which can be caused by parenteral nutrition, is postulated to promote the translocation of bowel endotoxin and may change the host immune responses to infection, thus accelerating the permeability of intestinal bacteria into the bloodstream.[@b19-idr-11-1225]

Compared with previous studies on CRPA, our study is the first to demonstrate that hematologic malignancy increases the risk of Carb-S/Ceph-S *P. aeruginosa* bacteremia. Certain predisposing factors for the association with hematologic malignancy, such as chemotherapeutic treatment and intravenous catheterization, often cause an intestinal mucosal break or ulceration that may potentially result in bacteremia,[@b20-idr-11-1225] while others, such as neutropenia and lymphopenia, may reduce the host cellular and humoral immunity and increase the risk of acquiring various pathogens, including *P. aeruginosa*.[@b21-idr-11-1225] Therefore, in patients receiving chemotherapy, for whom hematologic malignancy was diagnosed, *P. aeruginosa* bacteremia should be considered with special attention.

Not surprisingly, our study confirmed the association between antibiotic use and the appearance and spread of antimicrobial-resistant bacteria.[@b22-idr-11-1225] Although exposure to carbapenems was reported as a predictor of CRPA by other investigators,[@b16-idr-11-1225],[@b23-idr-11-1225] none of these studies evaluated Carb-R/Ceph-S *P. aeruginosa* specifically. One potential explanation is that the selection pressure exerted by previous carbapenem exposure may disrupt the gastrointestinal microflora and eradicate susceptible competing strains, thus elevating the chances of isolating Carb-R/Ceph-S *P. aeruginosa*. On the other hand, carbapenem resistance in these patients could be attributed to a mechanism involving a combination of efflux system overexpression and decreased OprD expression, as was observed in the present study. Considering that patients receiving carbapenem treatment may be placed at further risk for Carb-R/Ceph-S *P. aeruginosa* bacteremia, prudent use of antimicrobial agents is crucial to avoiding their further spread.

For clinical outcomes, we observed that the overall 30-day mortality rate was 27.0%, which was much higher than that reported from previous studies on CRPA.[@b24-idr-11-1225] In addition, the mortality rate of Carb-R/Ceph-S vs Carb-S/Ceph-S *P. aeruginosa* bacteremia was significantly different in these patients. Of the factors associated with mortality, including ICU admission and septic shock, were significantly linked to an increased risk of death. This could be explained by ICU patients having more severe underlying diseases and longer hospital stays, placing them at higher risk for poor outcomes. Similarly, septic shock, a very dangerous and potentially life-threatening infection, is physiologically regarded as a proinflammatory and procoagulant response against invading pathogens, resulting in a high mortality in these patients.[@b25-idr-11-1225] Unexpectedly, inadequate antibiotic therapy did not exhibit a significant relationship with mortality, probably due to the limited number of non-survivors in our study.

It is important to stress that because our analysis was conducted at a tertiary center, and the sample size was relatively small, our results might not be applicable to other settings. Moreover, the clonality of the resistant isolates was not investigated in our study, so potential outbreaks might not be ruled out. Nevertheless, our findings could provide some clinical predictors for physicians to identify some high-risk patients. In addition, this phenotype of Carb-R/Ceph-S *P. aeruginosa* deserves special concern, and the use of cephalosporin should be encouraged as a valuable therapeutic option for such infections based on the microbiology results of the patient.

In summary, this was the first comprehensive study to analyze the phenotype of Carb-R/Ceph-S *P. aeruginosa* bacteremia. Our findings showed that the decreased OprD expression and efflux system overexpression could be associated with Carb-R/Ceph-S *P. aeruginosa*. In addition, we identified some peculiar risk factors for Carb-R/Ceph-S and Carb-S/Ceph-S *P. aeruginosa* bacteremia, respectively. Therefore, strict control of carbapenem use and standard antibiotic stewardship are crucial to reduce the frequency of CRPA bacteremia.
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![Analysis of the resistance mechanisms for the four representative Carb-R/Ceph-S *Pseudomonas aeruginosa* isolates.\
**Notes:** \*Significant (*P*\<0.05). PA01 represents *P. aeruginasa* reference strain 01.](idr-11-1225Fig2){#f2-idr-11-1225}

![Kaplan--Meier probability estimate for the 30-day mortality of *Pseudomonas aeruginosa* bacteremia.\
**Note:** The blue line represents patients with bacteremia caused by Carb-R/Ceph-S *P. aeruginosa* strains; the orange line represents patients with Carb-S/Ceph-S *P. aeruginosa* strains (*P*=0.035 by a log-rank test).](idr-11-1225Fig3){#f3-idr-11-1225}

###### 

Univariate analysis of clinical features of patients with Carb-R/Ceph-S and Carb-S/Ceph-S *Pseudomonas aeruginosa* bacteremia.

  Risk factors                                               Case I        Case II       Controls        Case I VS Controls   Case II VS Controls   Case I VS Case II                                      
  ---------------------------------------------------------- ------------- ------------- --------------- -------------------- --------------------- -------------------- ------------- ------------------- -------------
  Male                                                       44 (69.8)     44 (69.8)     80 (63.5)       1.33 (0.70--2.55)    0.386                 1.33 (0.70--2.55)    0.386         1.00 (0.47--2.14)   1
  Surgical ward                                              36 (57.1)     27 (42.9)     55 (43.6)       1.72 (0.94--3.17)    0.080                 0.97 (0.53--1.78)    0.917         0.56 (0.28--1.14)   0.109
  Age, median, y (IQR)                                       63 (57--74)   62 (43--68)   59 (47--68)     --                   0.475                 --                   0.552         --                  0.656
  Elderly (≥60 y)                                            38 (60.3)     34 (53.9)     64 (50.8)       1.47 (0.80--2.72)    0.216                 1.14 (0.62--2.08)    0.681         1.30 (0.64--2.63)   0.471
  Transfer from another hospital                             31 (49.2)     35 (55.6)     62 (49.2)       1.00 (0.55--1.83)    1                     1.29 (0.7--2.37)     0.410         0.78 (0.39--1.56)   0.476
  30-day readmission                                         17 (27.0)     12 (19.0)     12 (9.5)        3.51 (1.56--7.93)    **0.002**             2.24 (0.94--5.31)    0.064         1.48 (0.73--3.0)    0.280
  Total length of stay, d (IQR)                              30 (20--75)   21 (12--42)   22 (12--33.5)   --                   0.165                 --                   0.171         --                  0.739
  30-day mortality                                           17 (27.0)     8 (12.7)      --              --                   --                    --                   --            2.54 (1.01--6.42)   **0.044**
  Underlying diseases and conditions                                                                                                                                                                       
  Diabetes                                                   12 (19)       9 (14.3)      23 (18.3)       1.05 (0.49--2.29)    0.895                 0.75 (0.32--1.73)    0.493         1.41 (0.55--3.63)   0.473
  Hypertension                                               18 (28.6)     16 (25.4)     34 (27.0)       1.08 (0.55--2.12)    0.818                 0.92 (0.46--1.84)    0.816         1.18 (0.53--2.58)   0.688
  Hematologic malignancy                                     20 (31.7)     20 (31.7)     14 (11.1)       3.72 (1.73--8.02)    **\<0.001**           3.72 (1.73--8.02)    **\<0.001**   1.00 (0.47--2.12)   1
  Solid malignancy                                           14 (22.2)     11 (17.5)     26 (20.6)       1.10 (0.53--2.30)    0.801                 0.81 (0.37--1.78)    0.604         1.35 (0.56--3.26)   0.503
  Respiratory failure                                        15 (23.8)     16 (25.4)     34 (26.9)       0.85 (0.42--1.70)    0.639                 0.92 (0.42--1.84)    0.816         0.92 (0.41--2.07)   0.836
  Heart disease                                              13 (20.6)     10 (15.9)     22 (17.5)       1.23 (0.57--2.64)    0.596                 0.89 (0.39--2.02)    0.784         1.38 (0.55--3.43)   0.489
  Hepatobiliary disease                                      22 (34.9)     19 (30.2)     22 (17.5)       2.53 (1.26--5.07)    **0.007**             2.04 (1.01--4.14)    **0.046**     1.24 (0.59--2.62)   0.568
  Gastrointestinal disease                                   16 (25.4)     15 (23.8)     28 (22.2)       1.00 (0.44--2.29)    1                     1.39 (0.64--2.99)    0.416         1.09 (0.48--2.45)   0.840
  Renal disease                                              13 (20.6)     11 (17.5)     27 (21.4)       0.95 (0.45--2.01)    0.900                 0.78 (0.36--1.69)    0.521         1.23 (0.50--3.0)    0.650
  Primary site of bacteremia                                                                                                                                                                               
  Urinary tract infection                                    13 (20.6)     10 (15.8)     28 (22.2)       0.91 (0.43--1.91)    0.803                 0.66 (0.30--1.46)    0.305         1.38 (0.55--3.43)   0.489
  Respiratory tract infection                                15 (23.8)     19 (30.2)     43 (34.1)       0.60 (0.30--1.20)    0.147                 0.83 (0.43--1.60)    0.584         0.72 (0.33--1.60)   0.422
  Intra-abdominal infection                                  15 (23.8)     4 (6.3)       5 (4.0)         7.56 (2.61--22.0)    **\<0.001**           NA                   NA            4.61 (1.44--14.8)   **0.006**
  Unknown                                                    20 (31.7)     30 (47.6)     50 (39.7)       0.71 (0.37--1.34)    0.287                 1.38 (0.75--2.54)    0.298         0.51 (0.25--1.06)   0.069
  Invasive procedures                                                                                                                                                                                      
  Mechanical ventilation                                     35 (55.6)     14 (22.2)     37 (29.4)       3.01 (1.61--5.63)    **\<0.001**           0.69 (0.34--1.39)    0.297         4.38 (2.02--9.49)   **\<0.001**
  Total parenteral nutrition                                 30 (47.6)     24 (38.1)     4 (3.2)         27.73 (9.12--84.3)   **\<0.001**           18.77 (6.14--57.4)   **\<0.001**   1.48 (0.73--3.0)    0.280
  Urinary catheter                                           39 (61.9)     30 (47.6)     62 (49.2)       1.68 (0.91--3.11)    0.099                 0.94 (0.51--1.72)    0.837         1.79 (0.88--3.63)   0.107
  Central venous catheter                                    37 (58.7)     25 (39.7)     29 (23.0)       4.76 (2.48--9.13)    **\<0.001**           2.2 (1.15--4.23)     **0.017**     2.16 (1.06--4.41)   **0.032**
  Nasogastric tube                                           33 (52.4)     16 (25.4)     51 (40.4)       1.62 (0.88--2.97)    0.121                 0.50 (0.26--0.98)    **0.041**     3.23 (1.52--6.86)   **0.002**
  Tracheal intubation                                        20 (31.7)     15 (23.8)     34 (27.0)       1.26 (0.65--2.44)    0.495                 0.85 (0.42--1.70)    0.639         1.49 (0.69--3.27)   0.320
  Drainage tube                                              22 (34.9)     24 (38.1)     38 (30.2)       1.24 (0.65--2.36)    0.507                 1.43 (0.76--2.69)    0.273         0.87 (0.42--1.80)   0.711
  Blood product transfusion                                  8 (12.7)      11 (17.5)     24 (19.0)       0.62 (0.26--1.47)    0.273                 0.90 (0.41--2.0)     0.791         0.69 (0.26--1.84)   0.455
  Surgery in the last 6 mo                                   15 (23.8)     17 (27.0)     31 (24.6)       0.96 (0.47--1.94)    0.905                 1.13 (0.57--2.25)    0.723         0.85 (0.38--1.89)   0.682
  Immunosuppressive state                                                                                                                                                                                  
  Severe anemia                                              4 (6.3)       6 (9.5)       15 (11.9)       0.50 (0.16--1.58)    0.231                 0.78 (0.29--2.12)    0.623         0.64 (0.17--2.40)   0.510
  Hypoproteinemia                                            46 (73)       37 (58.7)     61 (48.4)       2.88 (1.50--5.56)    **0.001**             1.52 (0.82--2.80)    0.181         1.90 (0.90--4.02)   0.091
  Hypokalemia                                                18 (28.6)     14 (22.2)     15 (11.9)       2.96 (1.37--6.38)    **0.004**             2.11 (0.95--4.72)    0.064         1.40 (0.63--3.14)   0.413
  Neutropenia                                                5 (7.9)       5 (7.9)       2 (1.6)         NA                   NA                    NA                   NA            1.00 (0.28--3.64)   1
  Chemoradiotherapy                                          8 (12.7)      15 (23.8)     15 (11.9)       1.08 (0.43--2.69)    0.875                 2.31 (1.05--5.10)    **0.035**     0.47 (0.18--1.19)   0.106
  Antimicrobial and antifungal agents exposure within 3 mo                                                                                                                                                 
  Antipseudomonal penicillins                                15 (23.8)     13 (20.6)     28 (22.2)       1.10 (0.54--2.24)    0.806                 0.91 (0.43--1.91)    0.803         1.20 (0.52--2.79)   0.668
  Cephalosporins                                             48 (76.2)     42 (66.7)     98 (77.8)       0.91 (0.45--1.87)    0.806                 0.57 (0.29--1.12)    0.100         1.60 (0.73--3.50)   0.237
  Aminoglycosides                                            13 (20.6)     5 (7.9)       22 (17.5)       1.23 (0.57--2.64)    0.596                 0.41 (0.15--1.13)    0.078         3.02 (1.01--9.05)   **0.042**
  Fluoroquinolones                                           22 (34.9)     20 (31.7)     29 (23.0)       1.80 (0.92--3.49)    0.082                 1.56 (0.79--3.05)    0.197         1.15 (0.55--2.42)   0.705
  Glycopeptides                                              29 (46)       21 (33.3)     42 (33.3)       1.71 (0.92--3.17)    0.089                 1.00 (0.53--1.90)    1             1.71 (0.83--3.51)   0.145
  Carbapenems                                                45 (71.4)     27 (42.9)     54 (42.9)       3.33 (1.74--6.39)    **\<0.001**           1.00 (0.54--1.84)    1             3.33 (1.59--6.99)   **0.001**
  Antifungal agents                                          28 (44.4)     25 (39.7)     35 (27.8)       2.08 (1.11--3.91)    **0.022**             1.71 (0.90--3.24)    0.097         1.22 (0.60--2.50)   0.588

**Notes:** Data are expressed as n (%) of patients for categorical variables and median (IQR) for continuous variables as appropriate. Bold face indicate values that are significant (*P*\<0.05)

**Abbreviations:** Case I, patients with Carb-R/Ceph-S *P. aeruginosa* bacteremia during hospitalization; Case II, patients with a positive blood culture for Carb-S/Ceph-S *P. aeruginosa* during hospitalization; OR, odds ratio; CI, confidence interval; ICU, intensive care unit; IQR, interquartile range; NA, not available.

###### 

Multivariate model of risk factors associated with Carb-R/Ceph-S and Carb-S/Ceph-S *Pseudomonas aeruginosa* bacteremia.

  Variables                    Case I VS Controls   Case II VS Controls   Case I VS Case II                                                           
  ---------------------------- -------------------- --------------------- ------------------- ------- ------------- ------------- ------ ------------ -----------
  30-day readmission           11.03                3.27--37.15           **\<0.001**         --      --            --            --     --           --
  Hematologic malignancy       --                   --                    --                  3.98    1.56--10.17   **0.004**     --     --           --
  Total parenteral nutrition   18.98                3.94--91.54           **\<0.001**         19.89   5.94--66.58   **\<0.001**   --     --           --
  Central venous catheter      5.85                 2.09--16.33           **0.001**           --      --            --            --     --           --
  Carbapenems                  11.41                3.38--38.56           **\<0.001**         --      --            --            2.65   1.17--6.01   **0.020**

**Notes:** Bold face indicate values that are significant (*P*\<0.05).

**Abbreviations:** Case I, patients with Carb-R/Ceph-S *P. aeruginosa* bacteremia during hospitalization; Case II, patients with a positive blood culture for Carb-S/Ceph-S *P. aeruginosa* during hospitalization; OR, odds ratio; CI, confidence interval.

###### 

Risk factors associated with 30-day mortality

  Variable                               Non-survival    Survival      Univariate            Multivariate                        
  -------------------------------------- --------------- ------------- --------------------- -------------- -------------------- -----------
  Host-related factors                                                                                                           
  Male gender                            21 (84.0)       67 (66.3)     2.66 (0.85--8.38)     0.085                               
  Elderly (≥60 y)                        20 (80.0)       51 (50.5)     3.92 (1.37--11.26)    **0.008**                           
  Surgical ward                          14 (56.0)       49 (48.5)     1.35 (0.56--3.26)     0.503                               
  Transfer from another hospital         13 (52.0)       53 (52.5)     0.98 (0.41--2.36)     0.966                               
  30-day readmission                     9 (36.0)        29 (28.7)     1.40 (0.56--3.52)     0.477                               
  ICU admission                          14 (56.0)       34 (33.7)     2.51 (1.03--6.11)     **0.039**      3.16 (1.11--8.95)    **0.031**
  Total length of stay, d (IQR)          22 (12--36.5)   28 (18--56)   --                    0.228                               
  Post-culture length of stay, d (IQR)   5 (1--17.5)     12 (3--29)    --                    0.170                               
  Hematologic malignancy                 12 (48.0)       29 (28.7)     2.29 (0.94--5.61)     0.065                               
  Hepatobiliary disease                  8 (32.0)        32 (31.7)     1.02 (0.40--2.60)     0.976                               
  MODS                                   14 (56.0)       22 (21.8)     4.57 (1.82--11.47).   **0.001**                           
  Septic shock                           15 (60.0)       28 (27.7)     3.91 (1.57--9.73)     **0.002**      4.22 (1.45--12.32)   **0.008**
  Microbiological-related factors                                                                                                
  High-risk source                       11 (44.0)       34 (33.7)     1.55 (0.64--3.77)     0.334                               
  Low-risk source                        13 (52.0)       44 (43.6)     1.40 (0.58--3.38)     0.448                               
  Antimicrobial-related factors                                                                                                  
  Adequate treatment                     10 (40)         35 (34.7)     1.25 (0.51--3.09)     0.617                               
  Inadequate treatment                   15 (60)         66 (65.3)     0.80 (0.32--1.96)     0.617                               

**Notes:** Bold face indicate values that are significant (P \< 0.05).

**Abbreviations:** ICU, intensive care unit; MODS, Multiple organ dysfunction syndrome; OR, odds ratio; CI, confidence interval.

[^1]: These authors contributed equally to this work
